OSI Pharma Acquired by Astellas for $4 Billion
Astellas Pharma Inc., Japan’s No.2 drugmaker, said on Sunday that it had agreed to buy U.S. biotech OSI Pharma (OSIP) for $4 billion in cash. Under the terms of the merger agreement, Astellas will add OSI’s blockbuster cancer drug Tarceva to its line-up and will increase its offer price to $57.50 per share, [...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here